Lonza discussed how adaptable manufacturing platforms could support in vivo mRNA–LNP delivery and reduce the cost and complexity of CMC for newer delivery approaches. The company’s process viewpoint focuses on scaling and controlling workflows without relying on individualized manufacturing steps typical of some n-of-1 cell therapies. The comments come as more developers shift from ex vivo cell work toward in vivo delivery modalities, including mRNA–LNP and viral vectors. Lonza emphasized the “vein-to-vein” control and manufacturing discipline needed to maintain quality when therapies are administered as off-the-shelf products. For CDMO customers, the signal is that CMC flexibility is increasingly treated as a development accelerator—not just a manufacturing feature.